Effects of Fluoxetine on Poststroke Dysphagia: A Clinical Retrospective Study

Jianting Huang, Xuanwei Liu, Xun Luo, Chunzhi Tang, Mingzhu Xu, Lisa Wood, Yulong Wang, Qing Mei Wang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: To investigate whether fluoxetine improves poststroke dysphagia and to detect the potential relationship between serum brain-derived neurotrophic factor (BDNF) levels and fluoxetine effects. Methods: In this retrospective study, 159 stroke patients who met our study criteria were included. In total, 110 patients were placed in the control group, and 49 patients were placed in the fluoxetine group. Demographic and clinical characteristics of the patients were collected for the baseline assessment. Functional independence measure scores and American speech-language-hearing association/functional communication measures scores for swallowing were collected to evaluate the patients’ swallowing function. Patients’ serums were collected at weeks 1 and 3 after admission, and serum BDNF levels were measured by enzyme-linked immunosorbent assay. T test, chi-squared test, and general linear model analysis were performed to determine the differences between the two groups. Results: A significantly higher improvement of swallowing function was observed in the fluoxetine group compared with that of the control group (P =.023). In addition, a general linear model analysis showed that the treatment of fluoxetine has a statistically significant effect on swallowing improvement after adjustment of swallowing score on admission, stroke types, and interval between the onset of stroke and admission (P =.022, R2 =.46, adjusted R2 =.446). There is no significant difference in the change of serum BDNF levels in the two groups (P =.269). Conclusions: This study suggests that treatment with fluoxetine in stroke patients with dysphagia may improve swallowing function. A placebo-controlled, randomized clinical trial is warranted to confirm this finding.

Original languageEnglish (US)
Pages (from-to)3320-3327
Number of pages8
JournalJournal of Stroke and Cerebrovascular Diseases
Volume27
Issue number11
DOIs
StatePublished - Nov 1 2018
Externally publishedYes

Fingerprint

Fluoxetine
Deglutition Disorders
Deglutition
Retrospective Studies
Brain-Derived Neurotrophic Factor
Stroke
Serum
Linear Models
American Speech-Language-Hearing Association
Social Adjustment
Control Groups
Clinical Studies
Randomized Controlled Trials
Enzyme-Linked Immunosorbent Assay
Communication
Placebos
Demography
Therapeutics

Keywords

  • brain-derived neurotrophic factor (BDNF)
  • dysphagia
  • fluoxetine
  • Poststroke
  • swallowing recovery

ASJC Scopus subject areas

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of Fluoxetine on Poststroke Dysphagia : A Clinical Retrospective Study. / Huang, Jianting; Liu, Xuanwei; Luo, Xun; Tang, Chunzhi; Xu, Mingzhu; Wood, Lisa; Wang, Yulong; Wang, Qing Mei.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 27, No. 11, 01.11.2018, p. 3320-3327.

Research output: Contribution to journalArticle

Huang, Jianting ; Liu, Xuanwei ; Luo, Xun ; Tang, Chunzhi ; Xu, Mingzhu ; Wood, Lisa ; Wang, Yulong ; Wang, Qing Mei. / Effects of Fluoxetine on Poststroke Dysphagia : A Clinical Retrospective Study. In: Journal of Stroke and Cerebrovascular Diseases. 2018 ; Vol. 27, No. 11. pp. 3320-3327.
@article{1d26f4e317684e4b87b2c3d4ba1fb254,
title = "Effects of Fluoxetine on Poststroke Dysphagia: A Clinical Retrospective Study",
abstract = "Background: To investigate whether fluoxetine improves poststroke dysphagia and to detect the potential relationship between serum brain-derived neurotrophic factor (BDNF) levels and fluoxetine effects. Methods: In this retrospective study, 159 stroke patients who met our study criteria were included. In total, 110 patients were placed in the control group, and 49 patients were placed in the fluoxetine group. Demographic and clinical characteristics of the patients were collected for the baseline assessment. Functional independence measure scores and American speech-language-hearing association/functional communication measures scores for swallowing were collected to evaluate the patients’ swallowing function. Patients’ serums were collected at weeks 1 and 3 after admission, and serum BDNF levels were measured by enzyme-linked immunosorbent assay. T test, chi-squared test, and general linear model analysis were performed to determine the differences between the two groups. Results: A significantly higher improvement of swallowing function was observed in the fluoxetine group compared with that of the control group (P =.023). In addition, a general linear model analysis showed that the treatment of fluoxetine has a statistically significant effect on swallowing improvement after adjustment of swallowing score on admission, stroke types, and interval between the onset of stroke and admission (P =.022, R2 =.46, adjusted R2 =.446). There is no significant difference in the change of serum BDNF levels in the two groups (P =.269). Conclusions: This study suggests that treatment with fluoxetine in stroke patients with dysphagia may improve swallowing function. A placebo-controlled, randomized clinical trial is warranted to confirm this finding.",
keywords = "brain-derived neurotrophic factor (BDNF), dysphagia, fluoxetine, Poststroke, swallowing recovery",
author = "Jianting Huang and Xuanwei Liu and Xun Luo and Chunzhi Tang and Mingzhu Xu and Lisa Wood and Yulong Wang and Wang, {Qing Mei}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2018.07.034",
language = "English (US)",
volume = "27",
pages = "3320--3327",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Effects of Fluoxetine on Poststroke Dysphagia

T2 - A Clinical Retrospective Study

AU - Huang, Jianting

AU - Liu, Xuanwei

AU - Luo, Xun

AU - Tang, Chunzhi

AU - Xu, Mingzhu

AU - Wood, Lisa

AU - Wang, Yulong

AU - Wang, Qing Mei

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: To investigate whether fluoxetine improves poststroke dysphagia and to detect the potential relationship between serum brain-derived neurotrophic factor (BDNF) levels and fluoxetine effects. Methods: In this retrospective study, 159 stroke patients who met our study criteria were included. In total, 110 patients were placed in the control group, and 49 patients were placed in the fluoxetine group. Demographic and clinical characteristics of the patients were collected for the baseline assessment. Functional independence measure scores and American speech-language-hearing association/functional communication measures scores for swallowing were collected to evaluate the patients’ swallowing function. Patients’ serums were collected at weeks 1 and 3 after admission, and serum BDNF levels were measured by enzyme-linked immunosorbent assay. T test, chi-squared test, and general linear model analysis were performed to determine the differences between the two groups. Results: A significantly higher improvement of swallowing function was observed in the fluoxetine group compared with that of the control group (P =.023). In addition, a general linear model analysis showed that the treatment of fluoxetine has a statistically significant effect on swallowing improvement after adjustment of swallowing score on admission, stroke types, and interval between the onset of stroke and admission (P =.022, R2 =.46, adjusted R2 =.446). There is no significant difference in the change of serum BDNF levels in the two groups (P =.269). Conclusions: This study suggests that treatment with fluoxetine in stroke patients with dysphagia may improve swallowing function. A placebo-controlled, randomized clinical trial is warranted to confirm this finding.

AB - Background: To investigate whether fluoxetine improves poststroke dysphagia and to detect the potential relationship between serum brain-derived neurotrophic factor (BDNF) levels and fluoxetine effects. Methods: In this retrospective study, 159 stroke patients who met our study criteria were included. In total, 110 patients were placed in the control group, and 49 patients were placed in the fluoxetine group. Demographic and clinical characteristics of the patients were collected for the baseline assessment. Functional independence measure scores and American speech-language-hearing association/functional communication measures scores for swallowing were collected to evaluate the patients’ swallowing function. Patients’ serums were collected at weeks 1 and 3 after admission, and serum BDNF levels were measured by enzyme-linked immunosorbent assay. T test, chi-squared test, and general linear model analysis were performed to determine the differences between the two groups. Results: A significantly higher improvement of swallowing function was observed in the fluoxetine group compared with that of the control group (P =.023). In addition, a general linear model analysis showed that the treatment of fluoxetine has a statistically significant effect on swallowing improvement after adjustment of swallowing score on admission, stroke types, and interval between the onset of stroke and admission (P =.022, R2 =.46, adjusted R2 =.446). There is no significant difference in the change of serum BDNF levels in the two groups (P =.269). Conclusions: This study suggests that treatment with fluoxetine in stroke patients with dysphagia may improve swallowing function. A placebo-controlled, randomized clinical trial is warranted to confirm this finding.

KW - brain-derived neurotrophic factor (BDNF)

KW - dysphagia

KW - fluoxetine

KW - Poststroke

KW - swallowing recovery

UR - http://www.scopus.com/inward/record.url?scp=85052742145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052742145&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2018.07.034

DO - 10.1016/j.jstrokecerebrovasdis.2018.07.034

M3 - Article

C2 - 30174226

AN - SCOPUS:85052742145

VL - 27

SP - 3320

EP - 3327

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 11

ER -